Skip to main content

Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer

This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
Interview with the Innovators
ESMO Early Breast Cancer
Videos — December 19, 2023
Nadia Harbeck, MD, PhD
Director, Breast Cancer
Professor, Conservative Oncology
LMU University Hospital
Munich, Germany

Interview with the Innovators Presents:
Emerging Data in Early Breast Cancer from ESMO 2023

We are pleased to announce the release of our latest Interview with the Innovators video series. This 3-part video series features expert commentary from Dr Nadia Harbeck, MD, PhD, Ludwig-Maximilians-University of Munich. In this video series, Dr Harbeck recaps data on adjuvant treatment for patients with HR+/HER2- early breast cancer, details new data on prognostic factors in breast cancer, and discusses recent trials investigating neoadjuvant immunotherapy.

Related Items

Patients Are at the Heart of Everything We Do
January 2024, Vol 14, No 1
Interview with the Innovators
New Developments on Prognostic Markers for Patients With Early Breast Cancer
By Nadia Harbeck, MD, PhD
Videos
Interview with the Innovators
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
By Nadia Harbeck, MD, PhD
Videos
Interview with the Innovators
Sanjay Juneja, MD, on the Approval of ORSERDU™
By Sanjay Juneja, MD
Videos
Interview with the Innovators